Strategic collaboration combines KYBORA’s global biopharma network with ACA Pharma’s 30–90 day Macau registration model to expedite access for rare disease and pediatric therapies in China. KYBORA and ACA Pharma…
Transforming Precision Medicine with Targeted Therapies Radiopharmaceuticals are transforming precision medicine by offering targeted diagnostic and therapeutic solutions. These innovative…
Spotlight on CAR-T, TIL, and TCR Therapies Cellular immunotherapies, including CAR-T, TIL, and TCR therapies, have transformed modern medicine, offering…
Precision Cancer Therapy Driving Investment and Innovation Antibody-drug conjugates (ADCs) are rapidly emerging as a transformative force in precision medicine,…
Inflammatory diseases, such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), psoriasis, and systemic lupus erythematosus (SLE), impact over 200…
Japan, the world’s third-largest pharmaceutical market, is undergoing transformative reforms in its pharmaceutical and medical device regulations. These changes are…
Transforming China’s Pharmaceutical Landscape The Chinese biopharma sector is undergoing a transformative evolution, driven by the emergence of NewCos—innovative, newly…
